The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 14, 2023

Filed:

Feb. 23, 2018
Applicant:

Hibercell, Inc., New York, NY (US);

Inventors:

Nandita Bose, Plymouth, MN (US);

Nadine Ottoson, Lakeville, MN (US);

Ben Harrison, Eagan, MN (US);

Jamie Lowe, Woodbury, MN (US);

Mark Uhlik, Indianapolis, IN (US);

Jeremy Graff, Indianapolis, IN (US);

Richard Huhn, St. Paul, MN (US);

Assignee:

HiberCell, Inc., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); A61K 31/716 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6854 (2013.01); A61K 31/716 (2013.01); G01N 2400/24 (2013.01); G01N 2800/52 (2013.01);
Abstract

This disclosure provides, in one aspect, dosing strategies for soluble β-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble β-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-β-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-β-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.


Find Patent Forward Citations

Loading…